surmount-1 trial tirzepatide non-diabetic weight loss for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity SURMOUNT-1: Tirzepatide Drastically Reduces Weight
Description
An exploratory analysis revealed that a subgroup of the participants in the ENGAGE trial who received a high dose of aducanumab exhibited slow decline, which was similar to that observed among the participants in the EMERGE trial
128 , e246e249 (2022)
The studys outcomes shed light on the significant implications that tirzepatide, like SURMOUNT-4, has on the realm of weight management and prevention
[DOI] [PubMed] [Google Scholar] 13
For additional safety information, please see our Safety Page
If you want 5 mg from a 20 mg/ml vial, you draw 0.25 ml
